Standard of care for patients with first‐line metastatic non‐squamous NSCLC––in the absence of an oncogenic driver such as an EGFR mutation or ALK translocation––is immune checkpoint blockade either alone or in combination with platinum‐based chemotherapy (pemetrexed or paclitaxel‐bevacizumab). The gene discussed is ALK; the disease is non-small cell lung carcinoma.